It’s worth trialing, but let’s be clear about the priors. The scant data we have are consistent with the expectation of a short-lived and non-anamnestic immune response after a first priming dose. It would be great if the SARS-CoV2 spike protein is the exception to this rule.
-
-
I don’t think you are seriously engaging with people who ask hard questions about this proposal. Yes trials should be run. Is there a way to advocate for that quietly, without spreading the *possibly* dangerous line that people only need one shot?
-
I’m happy to engage, but the one part that think most about is the public sphere. So the question you raise—and it’s penumbra—is the one I actually think most about, and has had most of my career focused around. I’m not new to that part at all. The immunology is for the experts.
- Show replies
New conversation -
-
-
They're looking at using half doses (at least for Moderna), which would be 2 doses of 50μg each instead of 100μg each. That is a better bet for durability and would also double available supply. Possibly could be approved based on existing Phase 2 data.
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.